Target product profiles & target candidate profiles

In the fight against malaria new medicines are an essential weapon. For the parts of the world where the current gold standard artemisinin combination therapies are active, significant improvements can still be made: for example combination medicines which allow for single dose regimens, cheaper, safer and more effective medicines, or improved stability under field conditions. For those parts of the world where the existing combinations show less than optimal activity, the priority is to have activity against emerging resistant strains, and other criteria take a secondary role.

For new medicines to be optimal in malaria control they must also be able to reduce transmission and prevent relapse of dormant forms: additional constraints on a combination medicine. In the absence of a highly effective vaccine, new medicines are also needed to protect patient populations.

In this paper, an outline definition of the ideal and minimally acceptable characteristics of the types of clinical candidate molecule which are needed (target candidate profiles) is suggested. In addition, the optimal and minimally acceptable characteristics of combination medicines are outlined (target product profiles). MMV presents now a suggested framework for combining the new candidates to produce the new medicines. Sustained investment over the next decade in discovery and development of new molecules is essential to enable the long-term delivery of the medicines needed to combat malaria.

Download the full paper:

Designing the next generation of medicines for malaria control and eradication
[PDF: 2.6Mb, 38 pages]

Summary of MMV’s Target Product Profiles (TPPs): 

TPP 1: SERCaP (Single Exposure Radical Cure and Prophylaxis) - Treatment of uncomplicated malaria in children and adults
[PDF: 1,680Kb, 7 pages]

TPP 2: SEC (Single Exposure chemoprotection) - A new medicine for chemoprotection
[PDF: 37Kb, 2 pages]

Summary of MMV’s Target Candidate Profiles (TCPs):

TCP 1: ‘Fast clearance’, reducing the initial parasite burden
[PDF: 47Kb, 3 pages]

TCP 2: Long duration partner to complete the clearance of the blood stage parasites
[PDF: 46Kb, 3 pages]

TCP 3: Targeting Plasmodium in the non-dividing parasite stages
[PDF: 47Kb, 4 pages]

TCP 4: Chemoprotection
[PDF: 44Kb, 3 pages]

The Global Malaria Portfolio

For more information about the global malaria portfolio, read the article: Malaria medicines: a glass half full? This Review, published in Nature Reviews Drug Discovery, discusses how the antimalarial drug discovery pipeline has changed over the past 10 years, grouped by the various target compound or product profiles, to assess progress and gaps, and to recommend priorities.